Literature DB >> 16140952

Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.

Wei-Sheng Xu1, Gisela Perez, Lang Ngo, Chang-Yun Gui, Paul A Marks.   

Abstract

Histone deacetylase (HDAC) inhibitors can induce various transformed cells to undergo growth arrest and/or death. Suberoylanilide hydroxamic acid (SAHA) is an HDAC inhibitor which is in phase I/II clinical trials and has shown antitumor activity in hematologic and solid tumors at doses well tolerated by patients. HDAC is the target for SAHA, but the mechanisms of the consequent induced death of transformed cells are not completely understood. In this study, we report that SAHA induced polyploidy in human colon cancer cell line HCT116 and human breast cancer cell lines, MCF-7, MDA-MB-231, and MBA-MD-468, but not in normal human embryonic fibroblast SW-38 and normal mouse embryonic fibroblasts. The polyploid cells lost the capacity for proliferation and committed to senescence. The induction of polyploidy was more marked in HCT116 p21WAF1-/- or HCT116 p53-/- cells than in wild-type HCT116. The development of senescence of SAHA-induced polyploidy cells was similar in all colon cell lines. The present findings indicate that the HDAC inhibitor could exert antitumor effects by inducing polyploidy, and this effect is more marked in transformed cells with nonfunctioning p21WAF1 or p53 genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140952     DOI: 10.1158/0008-5472.CAN-04-4608

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells.

Authors:  Sonam Sinha; Samriddhi Shukla; Sajid Khan; Trygve O Tollefsbol; Syed M Meeran
Journal:  Mol Cell Endocrinol       Date:  2015-02-25       Impact factor: 4.102

2.  Gcn5p plays an important role in centromere kinetochore function in budding yeast.

Authors:  Stefano Vernarecci; Prisca Ornaghi; Anacristina Bâgu; Enrico Cundari; Paola Ballario; Patrizia Filetici
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

3.  Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.

Authors:  Wen-Jing Shen; Dong-Qiu Dai; Yue Teng; Hong-Bo Liu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

Review 4.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Authors:  Paul A Marks
Journal:  Biochim Biophys Acta       Date:  2010-06-08

Review 5.  The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Authors:  Paul A Marks
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

6.  Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

Authors:  Todd M Pitts; Mark Morrow; Sara A Kaufman; John J Tentler; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

7.  Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Authors:  Bárbara Kunzler Souza; Patrícia Luciana da Costa Lopez; Pâmela Rossi Menegotto; Igor Araujo Vieira; Nathalia Kersting; Ana Lúcia Abujamra; André T Brunetto; Algemir L Brunetto; Lauro Gregianin; Caroline Brunetto de Farias; Carol J Thiele; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

8.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

9.  A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

Authors:  Marwan G Fakih; Lakshmi Pendyala; Gerald Fetterly; Karoli Toth; James A Zwiebel; Igor Espinoza-Delgado; Alan Litwin; Youcef M Rustum; Mary Ellen Ross; Julianne L Holleran; Merrill J Egorin
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

10.  Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Francis J Giles; John L Cleveland
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.